RxDoctor Payments Data

Santhi Voora

Nephrology · Los Angeles, CANPI 1669748851

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,000 of the $3,414 with a category attached, or 87.9%. Kaneka Medical America LLC accounts for 93.0% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $3,193, more than ten times the $25 reported in 2019.

$3,414in general payments, 2019–2025

Across 8 payments — averaging $426.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kaneka Medical America LLC$3K
  • Veloxis Pharmaceuticals, Inc.$120
  • Mallinckrodt Hospital Products Inc.$77
  • Viiv Healthcare Company$25
  • Merck$18
$104,871in research payments, 2019–2025

Across 2 payments — averaging $52,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veloxis Pharmaceuticals, Inc.$105K

What the payments were for

  • Speaking & faculty fees$3,00088%
  • Food & beverage$2758%
  • Education$1404%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,414 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024
$100,621
Medicare patients
259
Services billed
932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5021$165,117
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5023$164,512
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$81,430
Cinacalcet Hcl78$44,975
VeltassaPatiromer Calcium Sorbitex48$42,885
Valganciclovir Hcl93$36,964
LokelmaSodium Zirconium Cyclosilicate46$34,415
Envarsus XrTacrolimus26$24,081
NulojixBelatacept11$23,806
FarxigaDapagliflozin Propanediol18$10,130
Everolimus19$8,211
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$3,194
Mycophenolate Mofetil11$2,044
Humalog Kwikpen U-100Insulin Lispro17$1,905
Labetalol Hcl29$1,413

Paid to pharmacies, not to this prescriber.

Other nephrology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →